What is claimed is:

1. A salt, which is 4,4'-(((((2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(azanediyl))bis(carbonyl))bis(1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5-diyl))bis(ethane-2,1-diyl))bis(bicyclo[2.2.1]heptane-1-carboxylic acid) di-hydrochloric acid salt.

2. The salt of claim 1, having Form I, wherein Form I has at least one X-ray powder diffraction (XRPD) peak, in terms of 2-theta (± 0.2 degrees), selected from 5.7, 8.5, 9.6, 9.9, 11.8, 12.3, 13.1, 13.4, 13.8, 14.2, 14.5, 15.4, 15.8, 16.8, 17.3 and 17.6 degrees.

3. The salt of claim 2, having an X-ray powder diffraction pattern as substantially shown in Figure 7.

~~**4.** The salt of claim 2, having a DSC thermogram substantially as depicted in Figure 8.~~

~~**5.** The salt of claim 2, having a thermogravimetric analysis (TGA) thermogram substantially as depicted in Figure 9.~~

~~**6.** The salt of claim 2, having at least one X-ray powder diffraction (XRPD) peak, in terms of 2-theta (± 0.2 degrees), selected from 5.7, 8.5, 9.6, 9.9, 11.8, 12.3, 13.1, 13.4, 13.8, 14.2, 14.5, 15.4, 15.8, 16.8, 17.3 and 17.6 degrees.~~

~~**7.** The salt of claim 2, having at least two X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 5.7, 8.5, 9.6, 9.9, 11.8, 12.3, 13.1, 13.4, 13.8, 14.2, 14.5, 15.4, 15.8, 16.8, 17.3 and 17.6 degrees.~~

~~**8.** The salt of claim 2, having at least three X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 5.7, 8.5, 9.6, 9.9, 11.8, 12.3, 13.1, 13.4, 13.8, 14.2, 14.5, 15.4, 15.8, 16.8, 17.3 and 17.6 degrees.~~

~~**9.** The salt of claim 2, having at least four X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 5.7, 8.5, 9.6, 9.9, 11.8, 12.3, 13.1, 13.4, 13.8, 14.2, 14.5, 15.4, 15.8, 16.8, 17.3 and 17.6 degrees.~~

~~**10.** The salt of claim 2, having characteristic X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), at 5.7, 8.5, 9.6, 9.9, 11.8, 12.3, 13.1, 13.4, 13.8, 14.2, 14.5, 15.4, 15.8, 16.8, 17.3 and 17.6 degrees.~~

~~**11.**~~**4.** The salt of claim 2, having a first endothermic peak with an onset temperature at 31.1 ^{o}C and a maximum at 91.4 ^{o}C, and a second endothermic peak with an onset temperature at

231.0 ºC and a maximum at 236.4 ºC in a differential scanning calorimetry (DSC) thermogram.

~~12.~~**5.** The salt of claim 1, having Form II, wherein Form II has at least one X-ray powder diffraction (XRPD) peak, in terms of 2-theta (± 0.2 degrees), selected from 4.6, 6.9, 8.9, 11.2, 11.7, 13.2, 13.9, 14.3, 14.8, 16.0, 16.7, 17.2, 17.9, 25.3 and 25.6 degrees.

~~13.~~**6.** The salt of claim ~~12~~5, having an X-ray powder diffraction pattern as substantially shown in Figure 11.

~~**14.** The salt of claim 12, having a DSC thermogram substantially as depicted in Figure 12.~~

~~**15.** The salt of claim 12, having a thermogravimetric analysis (TGA) thermogram substantially as depicted in Figure 13.~~

~~**16.** The salt of claim 12, having at least one X-ray powder diffraction (XRPD) peak, in terms of 2-theta (± 0.2 degrees), selected from 4.6, 6.9, 8.9, 11.2, 11.7, 13.2, 13.9, 14.3, 14.8, 16.0, 16.7, 17.2, 17.9, 25.3 and 25.6 degrees.~~

~~**17.** The salt of claim 12, having at least two X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 4.6, 6.9, 8.9, 11.2, 11.7, 13.2, 13.9, 14.3, 14.8, 16.0, 16.7, 17.2, 17.9, 25.3 and 25.6 degrees.~~

~~**18.** The salt of claim 12, having at least three X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 4.6, 6.9, 8.9, 11.2, 11.7, 13.2, 13.9, 14.3, 14.8, 16.0, 16.7, 17.2, 17.9, 25.3 and 25.6 degrees.~~

~~**19.** The salt of claim 12, having at least four X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 4.6, 6.9, 8.9, 11.2, 11.7, 13.2, 13.9, 14.3, 14.8, 16.0, 16.7, 17.2, 17.9, 25.3 and 25.6 degrees.~~

~~**20.** The salt of claim 12, having characteristic X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), at 4.6, 6.9, 8.9, 11.2, 11.7, 13.2, 13.9, 14.3, 14.8, 16.0, 16.7, 17.2, 17.9, 25.3 and 25.6 degrees.~~

~~21.~~**7.** The salt of claim ~~12~~5, having a first endothermic peak with an onset temperature at 22.2 ^{o}C and a maximum at 89.7 ^{o}C, and a second endothermic peak with an onset temperature at 251.7 ^{o}C and a maximum at 258.3 ^{o}C in a differential scanning calorimetry (DSC) thermogram.

~~22.~~**8.** The salt of claim 1, having Form III, wherein Form III has at least one X-ray powder diffraction (XRPD) peak, in terms of 2-theta (± 0.2 degrees), selected from 9.2, 11.2, 14.9, 17.0, 17.8, 19.7, 24.4 and 25.9 degrees.

~~**23.**~~**9.** The salt of claim ~~22~~8, having an X-ray powder diffraction pattern as substantially shown in Figure 14.

~~**24.** The salt of claim 22, having a DSC thermogram substantially as depicted in Figure 15.~~

~~**25.** The salt of claim 22, having a thermogravimetric analysis (TGA) thermogram substantially as depicted in Figure 16.~~

~~**26.** The salt of claim 22, having at least one X-ray powder diffraction (XRPD) peak, in terms of 2-theta (± 0.2 degrees), selected from 9.2, 11.2, 14.9, 17.0, 17.8, 19.7, 24.4 and 25.9 degrees.~~

~~**27.** The salt of claim 22, having at least two X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 9.2, 11.2, 14.9, 17.0, 17.8, 19.7, 24.4 and 25.9 degrees.~~

~~**28.** The salt of claim 22, having at least three X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 9.2, 11.2, 14.9, 17.0, 17.8, 19.7, 24.4 and 25.9 degrees.~~

~~**29.** The salt of claim 22, having at least four X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 9.2, 11.2, 14.9, 17.0, 17.8, 19.7, 24.4 and 25.9 degrees.~~

~~**30.** The salt of claim 22, having characteristic X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), at 9.2, 11.2, 14.9, 17.0, 17.8, 19.7, 24.4 and 25.9 degrees.~~

~~**31.**~~**10.** The salt of claim ~~22~~8, having an endothermic peak with an onset temperature of 247 ± 3 ºC and a maximum at 258 ± 3 ºC in a differential scanning calorimetry (DSC) thermogram.

~~**32.**~~**11.** The salt of claim 1, having Form IV, wherein Form IV has at least one X-ray powder diffraction (XRPD) peak, in terms of 2-theta (± 0.2 degrees), selected from 5.4, 8.8, 10.9, 13.0, 15.1, 16.2, 17.5, 21.9 and 26.3 degrees.

~~**33.**~~**12.** The salt of claim ~~32~~11, having an X-ray powder diffraction pattern as substantially shown in Figure 17.

~~**34.** The salt of claim 32, having a DSC thermogram substantially as depicted in Figure 18.~~

~~**35.** The salt of claim 32, having a thermogravimetric analysis (TGA) thermogram substantially as depicted in Figure 19.~~

~~**36.** The salt of claim 32, having at least one X-ray powder diffraction (XRPD) peak, in terms of 2-theta (± 0.2 degrees), selected from 5.4, 8.8, 10.9, 13.0, 15.1, 16.2, 17.5, 21.9 and 26.3 degrees.~~

~~**37.** The salt of claim 32, having at least two X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 5.4, 8.8, 10.9, 13.0, 15.1, 16.2, 17.5, 21.9 and 26.3 degrees.~~

~~**38.** The salt of claim 32, having at least three X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 5.4, 8.8, 10.9, 13.0, 15.1, 16.2, 17.5, 21.9 and 26.3 degrees.~~

~~**39.** The salt of claim 32, having at least four X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 5.4, 8.8, 10.9, 13.0, 15.1, 16.2, 17.5, 21.9 and 26.3 degrees.~~

~~**40.** The salt of claim 32, having characteristic X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), at 5.4, 8.8, 10.9, 13.0, 15.1, 16.2, 17.5, 21.9 and 26.3 degrees.~~

~~**41.**~~**13.** The salt of claim ~~32~~11, having an endothermic peak with an onset temperature of 268 ± 3 ºC and a maximum at 273 ± 3 ºC in a differential scanning calorimetry (DSC) thermogram.

~~**42.**~~**14.** The salt of claim 1, having Form V, wherein Form V has at least one X-ray powder diffraction (XRPD) peak, in terms of 2-theta (± 0.2 degrees), selected from 5.8, 9.1, 13.4, 14.8, 16.6, 17.1, 18.1 and 19.3 degrees.

~~**43.**~~**15.** The salt of claim ~~42~~14, having an X-ray powder diffraction pattern as substantially shown in Figure 21.

~~**44.** The salt of claim 42, having a DSC thermogram substantially as depicted in Figure 22.~~

~~**45.** The salt of claim 42, having a thermogravimetric analysis (TGA) thermogram substantially as depicted in Figure 23.~~

~~**46.** The salt of claim 42, having at least one X-ray powder diffraction (XRPD) peak, in terms of 2-theta (± 0.2 degrees), selected from 5.8, 9.1, 13.4, 14.8, 16.6, 17.1, 18.1 and 19.3 degrees.~~

~~**47.** The salt of claim 42, having at least two X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 5.8, 9.1, 13.4, 14.8, 16.6, 17.1, 18.1 and 19.3 degrees.~~

~~**48.** The salt of claim 42, having at least three X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 5.8, 9.1, 13.4, 14.8, 16.6, 17.1, 18.1 and 19.3 degrees.~~

~~**49.** The salt of claim 42, having at least four X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 5.8, 9.1, 13.4, 14.8, 16.6, 17.1, 18.1 and 19.3 degrees.~~

~~**50.** The salt of claim 42, having characteristic X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), at 5.8, 9.1, 13.4, 14.8, 16.6, 17.1, 18.1 and 19.3 degrees.~~

~~**51.**~~**16.** The salt of claim ~~42~~14, having an endothermic peak with an onset temperature of 241 ± 3 ºC and a maximum at 249 ± 3 ºC in a differential scanning calorimetry (DSC) thermogram.

~~**52.**~~**17.** The salt of claim 1, having Form VII, wherein Form VII has at least one X-ray powder diffraction (XRPD) peak, in terms of 2-theta (± 0.2 degrees), selected from 5.7, 9.9, 11.5, 14.1, 14.9, 17.0 and 24.4 degrees.

~~**53.**~~**18.** The salt of claim ~~52~~17, having an X-ray powder diffraction pattern as substantially shown in Figure 29.

~~**54.** The salt of claim 52, having a DSC thermogram substantially as depicted in Figure 30.~~

~~**55.** The salt of claim 52, having a thermogravimetric analysis (TGA) thermogram substantially as depicted in Figure 31.~~

~~**56.** The salt of claim 52, having at least one X-ray powder diffraction (XRPD) peak, in terms of 2-theta (± 0.2 degrees), selected from 5.7, 9.9, 11.5, 14.1, 14.9, 17.0 and 24.4 degrees.~~

~~**57.** The salt of claim 52, having at least two X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 5.7, 9.9, 11.5, 14.1, 14.9, 17.0 and 24.4 degrees.~~

~~**58.** The salt of claim 52, having at least three X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 5.7, 9.9, 11.5, 14.1, 14.9, 17.0 and 24.4 degrees.~~

~~**59.** The salt of claim 52, having at least four X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 5.7, 9.9, 11.5, 14.1, 14.9, 17.0 and 24.4 degrees.~~

~~**60.** The salt of claim 52, having characteristic X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), at 5.7, 9.9, 11.5, 14.1, 14.9, 17.0 and 24.4 degrees.~~

~~61.~~19. The salt of claim ~~52~~17, having a first endothermic peak with an onset temperature at 44 ± 3 ºC and a maximum at 85 ± 3 ºC, and a second endothermic peak with an onset

temperature at 260 ± 3 ºC and a maximum at 274 ± 3 ºC in a differential scanning calorimetry (DSC) thermogram.

~~62.~~20. The salt of claim 1, having Form VIII, wherein Form VIII has at least one X-ray powder diffraction (XRPD) peak, in terms of 2-theta (± 0.2 degrees), selected from 6.6, 11.2, 13.1, 14.7, 16.7, 19.0 and 24.1 degrees.

~~63.~~21. The salt of claim ~~62~~20, having an X-ray powder diffraction pattern as substantially shown in Figure 33.

~~**64.** The salt of claim 62, having a DSC thermogram substantially as depicted in Figure 34.~~

~~**65.** The salt of claim 62, having a thermogravimetric analysis (TGA) thermogram substantially as depicted in Figure 35.~~

~~**66.** The salt of claim 62, having at least one X-ray powder diffraction (XRPD) peak, in terms of 2-theta (± 0.2 degrees), selected from 6.6, 11.2, 13.1, 14.7, 16.7, 19.0 and 24.1 degrees.~~

~~**67.** The salt of claim 62, having at least two X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 6.6, 11.2, 13.1, 14.7, 16.7, 19.0 and 24.1 degrees.~~

~~**68.** The salt of claim 62, having at least three X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 6.6, 11.2, 13.1, 14.7, 16.7, 19.0 and 24.1 degrees.~~

~~**69.** The salt of claim 62, having at least four X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 6.6, 11.2, 13.1, 14.7, 16.7, 19.0 and 24.1 degrees.~~

~~**70.** The salt of claim 62, having characteristic X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), at 6.6, 11.2, 13.1, 14.7, 16.7, 19.0 and 24.1 degrees.~~

~~71.~~22. The salt of claim ~~62~~20, having a first endothermic peak with an onset temperature at 44 ± 3 ºC and a maximum at 78 ± 3 ºC, and a second endothermic peak with an onset temperature at 246 ± 3 ºC and a maximum at 253 ± 3 ºC in a differential scanning calorimetry (DSC) thermogram.

~~72.~~**23.** The salt of claim 1, having Form IX, wherein Form IX has at least one X-ray powder diffraction (XRPD) peak, in terms of 2-theta (± 0.2 degrees), selected from 3.8, 6.6, 10.7, 13.1, 15.3, 16.3, 17.5 and 19.1 degrees.

~~73.~~**24.** The salt of claim ~~72~~23, having an X-ray powder diffraction pattern as substantially shown in Figure 37.

~~**74.** The salt of claim 72, having a DSC thermogram substantially as depicted in Figure 38.~~

~~**75.** The salt of claim 72, having a thermogravimetric analysis (TGA) thermogram substantially as depicted in Figure 39.~~

~~**76.** The salt of claim 72, having at least one X-ray powder diffraction (XRPD) peak, in terms of 2-theta (± 0.2 degrees), selected from 3.8, 6.6, 10.7, 13.1, 15.3, 16.3, 17.5 and 19.1 degrees.~~

~~**77.** The salt of claim 72, having at least two X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 3.8, 6.6, 10.7, 13.1, 15.3, 16.3, 17.5 and 19.1 degrees.~~

~~**78.** The salt of claim 72, having at least three X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 3.8, 6.6, 10.7, 13.1, 15.3, 16.3, 17.5 and 19.1 degrees.~~

~~**79.** The salt of claim 72, having at least four X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 3.8, 6.6, 10.7, 13.1, 15.3, 16.3, 17.5 and 19.1 degrees.~~

~~**80.** The salt of claim 72, having characteristic X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), at 3.8, 6.6, 10.7, 13.1, 15.3, 16.3, 17.5 and 19.1 degrees.~~

~~81.~~25. The salt of claim ~~72~~23, having a first endothermic peak with an onset temperature at 43 ± 3 ºC and a maximum at 64 ± 3 ºC, and a second endothermic peak at 116 ± 3 ºC and a maximum at 132 ± 3 ºC, and a third endothermic peak at 266 ± 3 ºC and a maximum at 276 ± 3 ºC in a differential scanning calorimetry (DSC) thermogram.

~~82.~~26. A salt, which is 4,4'-(((((2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(azanediyl))bis(carbonyl))bis(1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5-diyl))bis(ethane-2,1-diyl))bis(bicyclo[2.2.1]heptane-1-carboxylic acid) mono-hydrochloric acid salt.

~~83.~~27. The salt of claim ~~82~~26, having Form VI, wherein Form VI has at least one X-ray powder diffraction (XRPD) peak, in terms of 2-theta (± 0.2 degrees), selected from 6.4, 11.1, 12.6, 13.8, 14.6, 15.7, 16.9, 17.6, 19.0 and 19.5 degrees.

~~84.~~28. The salt of claim ~~83~~27, having an X-ray powder diffraction pattern as substantially shown in Figure 25.

85. The salt of claim 83, having a DSC thermogram substantially as depicted in Figure 26.

86. The salt of claim 83, having a thermogravimetric analysis (TGA) thermogram substantially as depicted in Figure 27.

87. The salt of claim 83, having at least one X-ray powder diffraction (XRPD) peak, in terms of 2-theta (± 0.2 degrees), selected from 6.4, 11.1, 12.6, 13.8, 14.6, 15.7, 16.9, 17.6, 19.0 and 19.5 degrees.

88. The salt of claim 83, having at least two X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 6.4, 11.1, 12.6, 13.8, 14.6, 15.7, 16.9, 17.6, 19.0 and 19.5 degrees.

89. The salt of claim 83, having at least three X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 6.4, 11.1, 12.6, 13.8, 14.6, 15.7, 16.9, 17.6, 19.0 and 19.5 degrees.

90. The salt of claim 83, having at least four X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 6.4, 11.1, 12.6, 13.8, 14.6, 15.7, 16.9, 17.6, 19.0 and 19.5 degrees.

91. The salt of claim 83, having characteristic X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), at 6.4, 11.1, 12.6, 13.8, 14.6, 15.7, 16.9, 17.6, 19.0 and 19.5 degrees.

92.29. The salt of claim 8327, having a first endothermic peak with an onset temperature at 44 ± 3 ºC and a maximum at 77 ± 3 ºC, and a second endothermic peak with an onset temperature at 244 ± 3 ºC and a maximum at 251 ± 3 ºC in a differential scanning calorimetry (DSC) thermogram.

93.30. A salt, which is 4,4'-(((((2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(azanediyl))bis(carbonyl))bis(1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5-diyl))bis(ethane-2,1-diyl))bis(bicyclo[2.2.1]heptane-1-carboxylic acid) di-sodium salt.

94.31. The salt of claim 9330, having an X-ray powder diffraction pattern as substantially shown in Figure 4.

95. The salt of claim 93, having a DSC thermogram substantially as depicted in Figure 5.

~~**96.** The salt of claim 93, having a thermogravimetric analysis (TGA) thermogram substantially as depicted in Figure 6.~~

~~97.~~32. The salt of claim ~~93~~30, having at least one X-ray powder diffraction (XRPD) peak, in terms of 2-theta (± 0.2 degrees), selected from 5.3, 7.1, 10.6, 13.9, 14.3, 16.1 and 17.4 degrees.

~~**98.** The salt of claim 93, having at least two X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 5.3, 7.1, 10.6, 13.9, 14.3, 16.1 and 17.4 degrees.~~

~~**99.** The salt of claim 93, having at least three X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 5.3, 7.1, 10.6, 13.9, 14.3, 16.1 and 17.4 degrees.~~

~~**100.** The salt of claim 93, having at least four X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 5.3, 7.1, 10.6, 13.9, 14.3, 16.1 and 17.4 degrees.~~

~~**101.** The salt of claim 93, having characteristic X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), at 5.3, 7.1, 10.6, 13.9, 14.3, 16.1 and 17.4 degrees.~~

~~102.~~33. The salt of claim ~~93~~30, having a first endothermic peak with an onset temperature of 47 ± 3 ºC and a maximum at 108 ± 3 ºC and a second endothermic peak with an onset temperature of 258 ± 3 ºC and a maximum at 280 ± 3 ºC in a differential scanning calorimetry (DSC) thermogram.

~~103.~~34. A solid form of 4,4'-(((((2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(azanediyl))bis(carbonyl))bis(1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5-diyl))bis(ethane-2,1-diyl))bis(bicyclo[2.2.1]heptane-1-carboxylic acid), wherein the solid form is crystalline.

~~104.~~35. The solid form of claim ~~103~~34, having an X-ray powder diffraction pattern as substantially shown in Figure 1.

~~**105.** The solid form of claim 103, having a DSC thermogram substantially as depicted in Figure 2.~~

~~**106.** The solid form of claim 103, having a thermogravimetric analysis (TGA) thermogram substantially as depicted in Figure 3.~~

~~107.~~36. The solid form of claim ~~103~~34, having at least one X-ray powder diffraction (XRPD) peak, in terms of 2-theta (± 0.2 degrees), selected from 6.2, 10.9, 11.3, 12.4, 13.7, 14.5, 15.5, 17.5, and 18.8 degrees.

~~**108.** The solid form of claim 103, having at least two X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 6.2, 10.9, 11.3, 12.4, 13.7, 14.5, 15.5, 17.5, and 18.8 degrees.~~

~~**109.** The solid form of claim 103, having at least three X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 6.2, 10.9, 11.3, 12.4, 13.7, 14.5, 15.5, 17.5, and 18.8 degrees.~~

~~**110.** The solid form of claim 103, having at least four X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), selected from 6.2, 10.9, 11.3, 12.4, 13.7, 14.5, 15.5, 17.5, and 18.8 degrees.~~

~~**111.** The solid form of claim 103, having characteristic X-ray powder diffraction (XRPD) peaks, in terms of 2-theta (± 0.2 degrees), at 6.2, 10.9, 11.3, 12.4, 13.7, 14.5, 15.5, 17.5, and 18.8 degrees.~~

~~112.~~37. The solid form of claim ~~103~~34, having a first endothermic peak with an onset temperature of 33 ± 3 ºC and a maximum at 70 ± 3 ºC and a second endothermic peak with an onset temperature of 244 ± 3 ºC and a maximum at 250 ± 3 ºC in a differential scanning calorimetry (DSC) thermogram.

~~113.~~38. A pharmaceutical composition comprising a salt of any one of claims ~~1-102~~ 1-33 or a solid form of any one of claims ~~103-112~~34-37, and a pharmaceutically acceptable carrier or excipient.

~~114.~~39. A solid oral dosage form comprising the pharmaceutical composition of claim ~~113~~38.

~~115.~~40. ~~A method of inhibiting PD-1/PD-L1 interaction, said method comprising administering to a patient~~ Use of a salt of any one of claims ~~1-102~~ 1-33 or a solid form of any one of claims ~~103-112~~34-37, in the manufacture of a medicament for inhibiting PD-1/PD-L1 interaction.

~~116.~~41. ~~A method of treating a disease or disorder associated with inhibition of PD-1/PD-L1 interaction, said method comprising administering to a patient in need thereof a therapeutically effective amount~~ Use of a salt of any one of claims ~~1-102~~ 1-33 or a solid form

of any one of claims ~~103-112~~34-37, in the manufacture of a medicament for treating a disease or disorder associated with inhibition of PD-1/PD-L1 interaction.

42. The use according to claim 41, wherein the disease or disorder is cancer or an infection.

43. The use according to claim 42, wherein the disease or disorder is cancer, and the cancer is a metastatic cancer that expresses PD-L1, lung cancer, non-small cell lung cancer, hepatic cancer, melanoma, cancer of the bladder, cancer of the urethra, renal cancer, or clear cell carcinoma.

~~**117.**~~**44.** ~~A method of enhancing, stimulating and/or increasing the immune response in a patient, said method comprising administering to the patient in need thereof a therapeutically~~

~~effective amount~~ Use of a salt of any one of claims ~~1-102~~ 1-33 or a solid form of any one of claims ~~103-112~~34-37, in the manufacture of a medicament for enhancing, stimulating and/or increasing the immune response in a patient.

~~118.~~45. A process of preparing the salt of claim 1, comprising reacting said Compound 1 with at least two equivalents of hydrochloric acid.

~~119.~~46. A process of preparing the salt of any one of claims ~~2-11~~2-4, comprising:

a) preparing a suspension of Compound 1 and at least 2 equivalents of hydrochloric acid in a solvent comprising acetone;

b) heating the suspension of a) to above room temperature to form a clear solution;

c) cooling the clear solution of b) to about room temperature;

d) adding a solvent comprising acetone to the mixture of c) to form a cloudy solution; and

e) filtering the cloudy solution of d) to provide said Form I as a solid.

~~120.~~47. A process of preparing Compound 1:



(Compound 1)

or a salt thereof, comprising:

reacting Compound 5-6:



(Compound 5-6)

with 4-(2-oxoethyl)bicyclo[2.2.1]heptane-1-carboxylic acid (Compound 5-4):



(Compound 5-4)

in the presence of a reducing agent to form said Compound 1, or a salt thereof.

~~**121.** The process of claim 120, wherein the reducing agent is sodium triacetoxyborohydride.~~

~~**122.** The process of any one of claims 120-121, wherein the reacting is performed in a solvent that comprises dichloromethane.~~

~~**123.** The process of any one of claims 120-121, wherein the reacting is performed in a solvent that does not comprise dichloromethane.~~

~~**124.** The process of any one of claims 120-121, wherein the reacting is performed in a solvent that comprises acetonitrile.~~

~~**125.**__**48.**__ The process of ~~any one of claims 120-124~~claim 47, wherein said Compound 5-6 is prepared by a process comprising:

deprotecting Compound 5-3a:



(Compound 5-3a)

to form said Compound 5-6, wherein P^1 is an amine protecting group.

~~**126.**~~**49.** The process of claim ~~125~~48, wherein the deprotecting comprises:

reacting said Compound 5-3a with hydrochloric acid in a solvent to form Compound 5-5:



(Compound 5-5); and

neutralizing said Compound 5-5 with base to form said Compound 5-6.

~~**127.** The process of claim 126, wherein the base is sodium bicarbonate.~~

~~**128.** The process of claim 125, wherein the deprotecting comprises reacting Compound 5-3a with hydrochloric acid in a solvent comprising methanol, followed by reaction with sodium bicarbonate in a solvent comprising water and THF to form said Compound 5-6.~~

~~**129.**~~**50.** The process of ~~any one of claims 125-128~~claim 48 or 49, wherein said Compound 5-3a is Compound 5-3:



(Compound 5-3)

~~**130.**~~**51.** The process of ~~any one of claims 125-128~~claim 48 or 49, wherein said Compound 5-3a is prepared by a process comprising:

reacting Compound 5-2a:



(Compound 5-2a)

with Compound 5-1:



(Compound 5-1)

in the presence of a base in a solvent to form said Compound 5-3a, wherein P^1 is an amine protecting group.

~~**131.** The process of claim 130, wherein the reacting of said Compound 5-2a with said Compound 5-1 is conducted in the presence of potassium 2-methylpropan-2-olate in a solvent comprising THF.~~

~~**132.**~~**52.** The process of ~~any one of claims 130-131~~claim 51, wherein said Compound 5-2a is Compound 5-2:



(Compound 5-2).

~~**133.**~~**53.** The process of ~~any one of claims 130-132~~claim 51 or 52, wherein said Compound 5-1 is prepared by a process comprising:

reacting Compound 6-1a:



(Compound 6-1a)

with Compound 2-3:



(Compound 2-3)

in the presence of a Suzuki catalyst and a base in a solvent to form said Compound 5-1, wherein:

each R^a is independently selected from H and C_{1-6} alkyl; or

each R^a, together with the oxygen atoms to which they are attached and the boron atom to which the oxygen atoms are attached, form a ring of formula , which is optionally substituted with 1, 2, 3, or 4 C_{1-4} alkyl groups.

~~**134.** The process of claim 133, wherein the catalyst is dichlorobis[di-tert-butyl(p-dimethylaminophenyl)phosphino]palladium.~~

~~**135.** The process of claim 133, wherein the reacting of Compound 6-1a and Compound 2-3 are carried out in the presence of dichlorobis[di-tert-butyl(p-dimethylaminophenyl)phosphino]palladium and potassium acetate in a solvent comprising dioxane and water.~~

~~**136.**~~**54.** The process of ~~any one of claims 133-135~~claim 53, wherein said Compound 6-1a is Compound 6-1:



(Compound 6-1).

~~137.~~**55.** A compound selected from Compound 5-3a, Compound 5-3, Compound 5-4, and Compound 5-1:



(Compound 5-3a)



(Compound 5-3)



(Compound 5-4)



(Compound 5-1)

or a salt thereof.